Findings

What do systematic reviews say?

2,119 questions · 2,206 findings · 117 reviews · Common Mental Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 387 · 17.5%GRADE not reported 111 · 5%Very low 635 · 28.8%Low 568 · 25.7%Moderate 449 · 20.4%High 56 · 2.5%

Levetiracetam vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Levetiracetam vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Antipsychotics vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

It is very uncertain whether comparison 4: antipsychotics changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 7 [0.45, 108.26]
1 study · 10 participants
Very low

Antipsychotics vs placebo

Withdrawals due to adverse events · adults with SAnD

It is very uncertain whether comparison 4: antipsychotics changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 0.71 [0.06, 8.9]
1 study · 12 participants
Very low

Antipsychotics vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Very low

Benzodiazepines vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 5: benzodiazepines may leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 4.03 [2.45, 6.65]
2 studies · 132 participants
Low

Benzodiazepines vs placebo

Relapse · adults with SAnD

Comparison 5: benzodiazepines showed no clear difference in relapse rate ‐ no. relapsed compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 0.12 [0.01, 2.14]
1 study · 36 participants
Low

Benzodiazepines vs placebo

Withdrawals due to adverse events · adults with SAnD

It is very uncertain whether comparison 5: benzodiazepines changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.68 [0.21, 13.13]
2 studies · 96 participants
Very low

Comparison 1: 5HT1A partial agonists vs placebo

Withdrawals due to adverse events · adults with SAnD

It is very uncertain whether comparison 1: 5HT1A partial agonists changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 3 [0.13, 68.26]
1 study · 30 participants
Very low

Benzodiazepines vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 135 participants
Very low

Benzodiazepines vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 75 participants
Low

Benzodiazepines vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 75 participants
Low

Beta‐blockers vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

It is very uncertain whether comparison 6: beta‐blockers changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.09 [0.63, 1.88]
2 studies · 97 participants
Very low

MAOIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 7: MAOIs may leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 2.36 [1.48, 3.75]
4 studies · 235 participants
Low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 218 participants
Very low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

MAOIs vs placebo

Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term) Post‐treatment: 1‐4 months · adults with SAnD

It is very uncertain whether comparison 7: MAOIs changes clinical Global Impressions scale change item (CGI‐I):no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.84 [1.02, 3.33]
2 studies · 113 participants
Very low

Comparison 8: NARIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

It is very uncertain whether comparison 8: NARIs changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 0.7 [0.19, 2.54]
1 study · 27 participants
Very low

Comparison 1: 5HT1A partial agonists vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low